从链霉素到贝达喹啉:抗结核药物临床试验发展70年历程回顾

From streptomycin to bedaquiline： overview of anti-TB drug clinical trials during the past 70 years

抗结核药物链霉素开启了人类医学史上药物临床试验的篇章,70年来肺结核化学治疗史上浓墨重彩地记录了抗结核药物联合化疗方案的演变、抗结核药物短程化疗方案的产生、缩短药物敏感肺结核治疗疗程方案的探索,以及缩短耐多药结核病治疗疗程方案的探索等重大药物临床试验事件.了解抗结核药物临床试验的发展历程,有助于我们更好地理解结核病治疗学的渊源和脉络,有助于我们思考和计划结核病临床科研的发展方向,以期为患者带来更适宜的治疗方案,最终实现消灭结核病的世纪梦想.

Streptomycin, an anti-TB drug, opened the first drug clinical trial in history of medicine. In the past 70 years, a series of key drug clinical trials have been recorded including combination therapy for TB, the development of short course chemotherapy, the exploration of shortening treatment for susceptible TB as well as shortening treatment for MDR-TB. Overview of anti-TB drug clinical trials development would help a better understanding of the origin and changes of TB chemotherapy, promote our thinking and planning for further TB clinical research with the aim to provide optimal treatment regimens for the patients and ultimately achieve the goal of ending TB epidemic in this century.